Optimized second-generation mRNA vaccine demonstrates improved protection against COVID-19
In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19—known as CVnCoV and developed by CureVac—reported approximately 48 percent efficacy against symptomatic disease. CV2CoV is a second generation ...
Nov 18, 2021
0
170